Hans Knöll Institute (HKI) Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2018
NCT03590600
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hans Knöll Institute (HKI) | Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institut

Active Ingredients

Drugs in Phase 1 Trials (1)

btz-043 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Communicable Diseases (Phase 1)

Infections (Phase 1)

Lung Diseases (Phase 1)

Mycobacterium Infections (Phase 1)

Tuberculosis (Phase 1)

Tuberculosis, Pulmonary (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1